Efficacy of antiplatelet therapy with ticagrelor monotherapy after short-term double antibody therapy in patients with acute coronary syndrome after PCI
10.12092/j.issn.1009-2501.2022.09.007
- Author:
Shengfeng PANG
1
;
Ningning WU
1
;
Ru LI
1
;
Jun CAO
1
;
Jing ZHANG
2
;
Shenghu HE
2
Author Information
1. Department of Cardiology, Taizhou Hospital of Traditional Chinese Medicine
2. Department of Cardiology, Subei People's Hospital of Jiangsu Province
- Publication Type:Journal Article
- Keywords:
acute coronary syndrome;
bleeding;
ischemic events;
percutaneous coronary intervention;
ticagrelor
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2022;27(9):1004-1009
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To observe the clinical efficacy of antiplatelet therapy with ticagrelor monotherapy after short-term double antibody therapy in patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI). METHODS: A total of 172 patients with ACS who had undergone PCI from October 2018 to April 2022 in our hospital and Subei People's Hospital of Jiangsu Province were selected and divided into three groups according to the patients' medication status: 50 patients in group A (tegretol alone group); 62 patients in group B (aspirin enteric coated tablets + tegretol group); and 60 patients in group C (aspirin enteric coated tablets + clopidogrel hydrogen sulfate group). The patients were observed for postoperative recurrent angina pectoris, in-stent restenosis, revascularization, heart failure, and bleeding. RESULTS: There were no significant differences in postoperative recurrent angina, in-stent restenosis, re-hematologic reconstruction, heart failure, and bleeding between the 3 groups. CONCLUSION: There is no increase in ischemic events, heart failure in patients treated with tegretol antiplatelet therapy alone after a short course of dual antibiotics after PCI and it reduces risk of bleeding.
